UBS Group
LIMN

UBS Group’s Liminatus Pharma LIMN Stock Holding History

UBS Group’s Portfolio LIMN Stock Details LIMN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.84K Sell
16,730
-37,848
-69% -$6.54K ﹤0.01% 9460
2026
Q1 		$9.39K Buy
54,578
+35,183
+181% +$18.8K ﹤0.01% 8442
2025
Q4 		$11.8K Sell
19,395
-21,131
-52% -$23.5K ﹤0.01% 8145
2025
Q3 		$67.7K Buy
40,526
+9,040
+29% +$39K ﹤0.01% 7357
2025
Q2 		$351K Buy
+31,486
New +$353K ﹤0.01% 6313

Other funds holding LIMN

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $12.2B AUM 47.93% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS Group's LIMN Position: Q2 2026 in Review

UBS Group reduced its Liminatus Pharma (LIMN) stake by 69% in Q2 2026, selling an estimated $6.54K and leaving 16,730 shares worth $1.84K. The position accounts for ﹤0.01% of the portfolio, ranked #9460.

UBS Group first reported a position in LIMN in Q2 2025 and has held it in 5 quarters since. The position peaked at $351K in Q2 2025. 9 funds tracked by Wall St. Rank hold LIMN as of Q2 2026.

  • UBS Group held 16,730 shares of Liminatus Pharma worth $1.84K as of Q2 2026.
  • UBS Group sold 37,848 Liminatus Pharma shares in Q2 2026, an estimated $6.54K.
  • Liminatus Pharma made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #9460 holding.
  • UBS Group first reported a position in Liminatus Pharma in Q2 2025 and has held it in 5 quarters since.
  • UBS Group's Liminatus Pharma position peaked at $351K in Q2 2025.
  • 9 funds tracked by Wall St. Rank held Liminatus Pharma as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.